ID   RNF31_HUMAN             Reviewed;        1072 AA.
AC   Q96EP0; A0A962; Q86VI2; Q8TEI0; Q96GB4; Q96NF1; Q9H5F1; Q9NWD2;
DT   15-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   10-MAY-2017, entry version 158.
DE   RecName: Full=E3 ubiquitin-protein ligase RNF31;
DE            EC=2.3.2.27;
DE   AltName: Full=HOIL-1-interacting protein {ECO:0000303|PubMed:22863777};
DE            Short=HOIP {ECO:0000303|PubMed:22863777};
DE   AltName: Full=RING finger protein 31 {ECO:0000312|HGNC:HGNC:16031};
DE   AltName: Full=RING-type E3 ubiquitin transferase RNF31 {ECO:0000305};
DE   AltName: Full=Zinc in-between-RING-finger ubiquitin-associated domain protein {ECO:0000303|PubMed:15093743};
GN   Name=RNF31 {ECO:0000312|HGNC:HGNC:16031};
GN   Synonyms=ZIBRA {ECO:0000303|PubMed:15093743};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), ALTERNATIVE SPLICING, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=15093743; DOI=10.1016/j.yexcr.2004.01.019;
RA   Thompson H.G.R., Harris J.W., Lin L., Brody J.P.;
RT   "Identification of the protein Zibra, its genomic organization,
RT   regulation, and expression in breast cancer cells.";
RL   Exp. Cell Res. 295:448-459(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), IDENTIFICATION IN THE LUBAC
RP   COMPLEX, FUNCTION OF THE LUBAC COMPLEX, AND MUTAGENESIS OF CYS-699;
RP   CYS-702; CYS-871 AND CYS-874.
RX   PubMed=17006537; DOI=10.1038/sj.emboj.7601360;
RA   Kirisako T., Kamei K., Murata S., Kato M., Fukumoto H., Kanie M.,
RA   Sano S., Tokunaga F., Tanaka K., Iwai K.;
RT   "A ubiquitin ligase complex assembles linear polyubiquitin chains.";
RL   EMBO J. 25:4877-4887(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ILE-1061.
RC   TISSUE=Embryo, and Hair follicle dermal papilla;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 526-1072 (ISOFORMS 1/3).
RC   TISSUE=Spleen;
RX   PubMed=12693554; DOI=10.1093/dnares/10.1.49;
RA   Jikuya H., Takano J., Kikuno R., Hirosawa M., Nagase T., Nomura N.,
RA   Ohara O.;
RT   "Characterization of long cDNA clones from human adult spleen. II. The
RT   complete sequences of 81 cDNA clones.";
RL   DNA Res. 10:49-57(2003).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-466, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-466, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   POLYUBIQUITIN-BINDING, FUNCTION OF THE LUBAC COMPLEX, ASSOCIATION WITH
RP   TNF-RSC, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=20005846; DOI=10.1016/j.molcel.2009.10.013;
RA   Haas T.L., Emmerich C.H., Gerlach B., Schmukle A.C., Cordier S.M.,
RA   Rieser E., Feltham R., Vince J., Warnken U., Wenger T., Koschny R.,
RA   Komander D., Silke J., Walczak H.;
RT   "Recruitment of the linear ubiquitin chain assembly complex stabilizes
RT   the TNF-R1 signaling complex and is required for TNF-mediated gene
RT   induction.";
RL   Mol. Cell 36:831-844(2009).
RN   [11]
RP   FUNCTION OF THE LUBAC COMPLEX.
RX   PubMed=19136968; DOI=10.1038/ncb1821;
RA   Tokunaga F., Sakata S., Saeki Y., Satomi Y., Kirisako T., Kamei K.,
RA   Nakagawa T., Kato M., Murata S., Yamaoka S., Yamamoto M., Akira S.,
RA   Takao T., Tanaka K., Iwai K.;
RT   "Involvement of linear polyubiquitylation of NEMO in NF-kappaB
RT   activation.";
RL   Nat. Cell Biol. 11:123-132(2009).
RN   [12]
RP   IDENTIFICATION IN THE LUBAC COMPLEX, AND FUNCTION.
RX   PubMed=21455173; DOI=10.1038/nature09816;
RA   Gerlach B., Cordier S.M., Schmukle A.C., Emmerich C.H., Rieser E.,
RA   Haas T.L., Webb A.I., Rickard J.A., Anderton H., Wong W.W.,
RA   Nachbur U., Gangoda L., Warnken U., Purcell A.W., Silke J.,
RA   Walczak H.;
RT   "Linear ubiquitination prevents inflammation and regulates immune
RT   signalling.";
RL   Nature 471:591-596(2011).
RN   [13]
RP   IDENTIFICATION IN THE LUBAC COMPLEX, AND FUNCTION.
RX   PubMed=21455180; DOI=10.1038/nature09815;
RA   Tokunaga F., Nakagawa T., Nakahara M., Saeki Y., Taniguchi M.,
RA   Sakata S., Tanaka K., Nakano H., Iwai K.;
RT   "SHARPIN is a component of the NF-kappaB-activating linear ubiquitin
RT   chain assembly complex.";
RL   Nature 471:633-636(2011).
RN   [14]
RP   IDENTIFICATION IN THE LUBAC COMPLEX, FUNCTION, DOMAIN RANBP2-TYPE,
RP   UBIQUITIN-BINDING, AND MUTAGENESIS OF CYS-699; CYS-702; CYS-871 AND
RP   CYS-874.
RX   PubMed=21455181; DOI=10.1038/nature09814;
RA   Ikeda F., Deribe Y.L., Skanland S.S., Stieglitz B., Grabbe C.,
RA   Franz-Wachtel M., van Wijk S.J., Goswami P., Nagy V., Terzic J.,
RA   Tokunaga F., Androulidaki A., Nakagawa T., Pasparakis M., Iwai K.,
RA   Sundberg J.P., Schaefer L., Rittinger K., Macek B., Dikic I.;
RT   "SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB
RT   activity and apoptosis.";
RL   Nature 471:637-641(2011).
RN   [15]
RP   FUNCTION, DOMAIN RING, DOMAIN LDD, AND ENZYME MECHANISM.
RX   PubMed=22863777; DOI=10.1038/emboj.2012.217;
RA   Smit J.J., Monteferrario D., Noordermeer S.M., van Dijk W.J.,
RA   van der Reijden B.A., Sixma T.K.;
RT   "The E3 ligase HOIP specifies linear ubiquitin chain assembly through
RT   its RING-IBR-RING domain and the unique LDD extension.";
RL   EMBO J. 31:3833-3844(2012).
RN   [16]
RP   INTERACTION WITH RBCK1/HOIL1.
RX   PubMed=22430200; DOI=10.1038/embor.2012.24;
RA   Yagi H., Ishimoto K., Hiromoto T., Fujita H., Mizushima T., Uekusa Y.,
RA   Yagi-Utsumi M., Kurimoto E., Noda M., Uchiyama S., Tokunaga F.,
RA   Iwai K., Kato K.;
RT   "A non-canonical UBA-UBL interaction forms the linear-ubiquitin-chain
RT   assembly complex.";
RL   EMBO Rep. 13:462-468(2012).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383 AND SER-466, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH OTULIN.
RX   PubMed=23708998; DOI=10.1038/nature12296;
RA   Rivkin E., Almeida S.M., Ceccarelli D.F., Juang Y.C., Maclean T.A.,
RA   Srikumar T., Huang H., Dunham W.H., Fukumura R., Xie G., Gondo Y.,
RA   Raught B., Gingras A.C., Sicheri F., Cordes S.P.;
RT   "The linear ubiquitin-specific deubiquitinase gumby regulates
RT   angiogenesis.";
RL   Nature 498:318-324(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383 AND SER-466, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   INTERACTION WITH CYLD.
RX   PubMed=26997266; DOI=10.1016/j.celrep.2016.02.062;
RA   Hrdinka M., Fiil B.K., Zucca M., Leske D., Bagola K., Yabal M.,
RA   Elliott P.R., Damgaard R.B., Komander D., Jost P.J., Gyrd-Hansen M.;
RT   "CYLD limits Lys63- and Met1-linked ubiquitin at receptor complexes to
RT   regulate innate immune signaling.";
RL   Cell Rep. 14:2846-2858(2016).
RN   [21]
RP   STRUCTURE BY NMR OF 779-851.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the IBR domain of the RING finger protein 31.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-184 IN COMPLEX WITH OTULIN,
RP   UBIQUITINATION, DOMAIN, INTERACTION WITH OTULIN, IDENTIFICATION IN THE
RP   LUBAC COMPLEX, AND MUTAGENESIS OF TYR-82; ASN-85; LYS-99; ASN-101;
RP   ASN-102 AND VAL-104.
RX   PubMed=24726323; DOI=10.1016/j.molcel.2014.03.018;
RA   Elliott P.R., Nielsen S.V., Marco-Casanova P., Fiil B.K.,
RA   Keusekotten K., Mailand N., Freund S.M., Gyrd-Hansen M., Komander D.;
RT   "Molecular basis and regulation of OTULIN-LUBAC interaction.";
RL   Mol. Cell 54:335-348(2014).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 1-179 IN COMPLEX WITH OTULIN,
RP   AND X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1-179 IN COMPLEX WITH
RP   VCP.
RX   PubMed=24726327; DOI=10.1016/j.molcel.2014.03.016;
RA   Schaeffer V., Akutsu M., Olma M.H., Gomes L.C., Kawasaki M., Dikic I.;
RT   "Binding of OTULIN to the PUB domain of HOIP controls NF-kappaB
RT   signaling.";
RL   Mol. Cell 54:349-361(2014).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase component of the LUBAC
CC       complex which conjugates linear ('Met-1'-linked) polyubiquitin
CC       chains to substrates and plays a key role in NF-kappa-B activation
CC       and regulation of inflammation (PubMed:17006537, PubMed:19136968,
CC       PubMed:20005846, PubMed:21455173, PubMed:21455180,
CC       PubMed:21455181, PubMed:22863777). LUBAC conjugates linear
CC       polyubiquitin to IKBKG and RIPK1 and is involved in activation of
CC       the canonical NF-kappa-B and the JNK signaling pathways
CC       (PubMed:17006537, PubMed:19136968, PubMed:20005846,
CC       PubMed:21455173, PubMed:21455180, PubMed:21455181,
CC       PubMed:22863777). Linear ubiquitination mediated by the LUBAC
CC       complex interferes with TNF-induced cell death and thereby
CC       prevents inflammation (PubMed:21455173). LUBAC is proposed to be
CC       recruited to the TNF-R1 signaling complex (TNF-RSC) following
CC       polyubiquitination of TNF-RSC components by BIRC2 and/or BIRC3 and
CC       to conjugate linear polyubiquitin to IKBKG and possibly other
CC       components contributing to the stability of the complex
CC       (PubMed:20005846). Together with otulin, the LUBAC complex
CC       regulates the canonical Wnt signaling during angiogenesis. Binds
CC       polyubiquitin of different linkage types (PubMed:23708998).
CC       {ECO:0000269|PubMed:17006537, ECO:0000269|PubMed:19136968,
CC       ECO:0000269|PubMed:20005846, ECO:0000269|PubMed:21455173,
CC       ECO:0000269|PubMed:21455180, ECO:0000269|PubMed:21455181,
CC       ECO:0000269|PubMed:22863777, ECO:0000269|PubMed:23708998}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- SUBUNIT: Component of the LUBAC complex (linear ubiquitin chain
CC       assembly complex) which consists of SHARPIN, RBCK1 and RNF31
CC       (PubMed:17006537, PubMed:21455173, PubMed:21455180,
CC       PubMed:21455181). LUBAC has a MW of approximative 600 kDa
CC       suggesting a heteromultimeric assembly of its subunits
CC       (PubMed:17006537, PubMed:21455173, PubMed:21455180,
CC       PubMed:21455181). Associates with the TNF-R1 signaling complex
CC       (TNF-RSC) in a stimulation-dependent manner (PubMed:20005846).
CC       Interacts (via the PUB domain) with otulin (via the PIM motif);
CC       the interaction is direct (PubMed:23708998, PubMed:24726323,
CC       PubMed:24726327). Interacts (via the PUB domain) with VCP (via the
CC       PIM motif) (PubMed:24726327). Interacts with CYLD
CC       (PubMed:26997266). Interacts with MUSK (By similarity).
CC       {ECO:0000250|UniProtKB:Q924T7, ECO:0000269|PubMed:17006537,
CC       ECO:0000269|PubMed:20005846, ECO:0000269|PubMed:21455173,
CC       ECO:0000269|PubMed:21455180, ECO:0000269|PubMed:21455181,
CC       ECO:0000269|PubMed:22430200, ECO:0000269|PubMed:23708998,
CC       ECO:0000269|PubMed:24726323, ECO:0000269|PubMed:24726327,
CC       ECO:0000269|PubMed:26997266}.
CC   -!- INTERACTION:
CC       Q08117:AES; NbExp=3; IntAct=EBI-10225152, EBI-717810;
CC       Q9QYP6:Azi2 (xeno); NbExp=2; IntAct=EBI-948111, EBI-6115874;
CC       Q8N4L8:CCDC24; NbExp=3; IntAct=EBI-10225152, EBI-1104933;
CC       Q9BYQ4:KRTAP9-2; NbExp=3; IntAct=EBI-10225152, EBI-1044640;
CC       Q9BYM8:RBCK1; NbExp=20; IntAct=EBI-948111, EBI-2340624;
CC       Q9H0F6:SHARPIN; NbExp=2; IntAct=EBI-948111, EBI-3942966;
CC       P84022:SMAD3; NbExp=2; IntAct=EBI-948111, EBI-347161;
CC       Q5TAL4:SNRPC; NbExp=3; IntAct=EBI-10225152, EBI-10246938;
CC       Q4VA12:Traf1 (xeno); NbExp=2; IntAct=EBI-948111, EBI-6116765;
CC       Q9Y5U2:TSSC4; NbExp=3; IntAct=EBI-10225152, EBI-717229;
CC       Q6EMK4:VASN; NbExp=3; IntAct=EBI-10225152, EBI-10249550;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q924T7}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q96EP0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96EP0-2; Sequence=VSP_009647, VSP_009648;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q96EP0-3; Sequence=VSP_014006, VSP_014007;
CC   -!- TISSUE SPECIFICITY: Expressed in both normal and transformed
CC       breast epithelial cell lines. {ECO:0000269|PubMed:15093743}.
CC   -!- DOMAIN: The PUB domain mediates interaction with the PIM motifs of
CC       VCP and RNF31, with a strong preference for RNF31.
CC       {ECO:0000269|PubMed:24726323, ECO:0000269|PubMed:24726327}.
CC   -!- DOMAIN: The RanBP2-type zinc fingers mediate the specific
CC       interaction with ubiquitin. {ECO:0000269|PubMed:21455181}.
CC   -!- DOMAIN: The UBA domain mediates association with RBCK1/HOIL1 via
CC       interaction with its UBL domain.
CC   -!- DOMAIN: RING 1 and IBR zinc-fingers catalyze the first step
CC       transfer of ubiquitin from the E2 onto RING 2, to transiently form
CC       a HECT-like covalent thioester intermediate.
CC       {ECO:0000269|PubMed:22863777}.
CC   -!- DOMAIN: The linear ubiquitin chain determining domain (LDD)
CC       mediates the final transfer of ubiquitin from RING 2 onto the N-
CC       terminus of a target ubiquitin. {ECO:0000269|PubMed:22863777}.
CC   -!- PTM: Autoubiquitinated. Interaction with OTULIN is required to
CC       prevent formation of 'Met-1'-linked polyubiquitin chains.
CC       {ECO:0000269|PubMed:24726323}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15675.1; Type=Erroneous termination; Positions=1060; Note=Translated as Glu.; Evidence={ECO:0000305};
CC       Sequence=BAB15675.1; Type=Frameshift; Positions=1036; Evidence={ECO:0000305};
CC       Sequence=BAB15675.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC       Sequence=BAB70948.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY256461; AAP12522.1; -; mRNA.
DR   EMBL; AB265810; BAF35583.1; -; mRNA.
DR   EMBL; AK000973; BAA91450.1; -; mRNA.
DR   EMBL; AK027154; BAB15675.1; ALT_FRAME; mRNA.
DR   EMBL; AK055542; BAB70948.1; ALT_INIT; mRNA.
DR   EMBL; AK291247; BAF83936.1; -; mRNA.
DR   EMBL; AL136295; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471078; EAW66098.1; -; Genomic_DNA.
DR   EMBL; BC009821; AAH09821.3; -; mRNA.
DR   EMBL; BC012077; AAH12077.1; -; mRNA.
DR   EMBL; BC017376; AAH17376.3; -; mRNA.
DR   EMBL; AK074144; BAB84970.1; -; mRNA.
DR   CCDS; CCDS41931.1; -. [Q96EP0-1]
DR   CCDS; CCDS81792.1; -. [Q96EP0-3]
DR   RefSeq; NP_001297261.1; NM_001310332.1. [Q96EP0-3]
DR   RefSeq; NP_060469.4; NM_017999.4. [Q96EP0-1]
DR   UniGene; Hs.375217; -.
DR   UniGene; Hs.434081; -.
DR   PDB; 2CT7; NMR; -; A=779-851.
DR   PDB; 4DBG; X-ray; 2.71 A; B=480-636.
DR   PDB; 4JUY; X-ray; 2.40 A; A/B=1-180.
DR   PDB; 4LJO; X-ray; 1.56 A; A=853-1072.
DR   PDB; 4LJP; X-ray; 2.15 A; A=853-1072.
DR   PDB; 4LJQ; X-ray; 2.45 A; A/B/C/D=853-1072.
DR   PDB; 4OWF; X-ray; 2.00 A; G=350-379.
DR   PDB; 4OYJ; X-ray; 3.00 A; A/B/C/D/E/F/G/H/I/J/K/L/M=1-184.
DR   PDB; 4OYK; X-ray; 2.00 A; A/B=3-179.
DR   PDB; 4P09; X-ray; 1.70 A; A=1-179.
DR   PDB; 4P0A; X-ray; 2.30 A; A/C=1-179.
DR   PDB; 4P0B; X-ray; 2.70 A; A/C=1-179.
DR   PDB; 5EDV; X-ray; 3.48 A; A/B=696-1072.
DR   PDB; 5LJN; X-ray; 2.70 A; A/B=5-176.
DR   PDBsum; 2CT7; -.
DR   PDBsum; 4DBG; -.
DR   PDBsum; 4JUY; -.
DR   PDBsum; 4LJO; -.
DR   PDBsum; 4LJP; -.
DR   PDBsum; 4LJQ; -.
DR   PDBsum; 4OWF; -.
DR   PDBsum; 4OYJ; -.
DR   PDBsum; 4OYK; -.
DR   PDBsum; 4P09; -.
DR   PDBsum; 4P0A; -.
DR   PDBsum; 4P0B; -.
DR   PDBsum; 5EDV; -.
DR   PDBsum; 5LJN; -.
DR   ProteinModelPortal; Q96EP0; -.
DR   SMR; Q96EP0; -.
DR   BioGrid; 120389; 72.
DR   DIP; DIP-44034N; -.
DR   IntAct; Q96EP0; 28.
DR   MINT; MINT-3377714; -.
DR   STRING; 9606.ENSP00000315112; -.
DR   iPTMnet; Q96EP0; -.
DR   PhosphoSitePlus; Q96EP0; -.
DR   BioMuta; RNF31; -.
DR   DMDM; 45477216; -.
DR   EPD; Q96EP0; -.
DR   MaxQB; Q96EP0; -.
DR   PaxDb; Q96EP0; -.
DR   PeptideAtlas; Q96EP0; -.
DR   PRIDE; Q96EP0; -.
DR   DNASU; 55072; -.
DR   Ensembl; ENST00000324103; ENSP00000315112; ENSG00000092098. [Q96EP0-1]
DR   Ensembl; ENST00000559275; ENSP00000453574; ENSG00000092098. [Q96EP0-3]
DR   GeneID; 55072; -.
DR   KEGG; hsa:55072; -.
DR   UCSC; uc001wml.2; human. [Q96EP0-1]
DR   CTD; 55072; -.
DR   DisGeNET; 55072; -.
DR   GeneCards; RNF31; -.
DR   HGNC; HGNC:16031; RNF31.
DR   HPA; CAB009063; -.
DR   HPA; HPA048745; -.
DR   MalaCards; RNF31; -.
DR   MIM; 612487; gene.
DR   neXtProt; NX_Q96EP0; -.
DR   OpenTargets; ENSG00000092098; -.
DR   PharmGKB; PA134906471; -.
DR   eggNOG; KOG1812; Eukaryota.
DR   eggNOG; ENOG410XS1H; LUCA.
DR   GeneTree; ENSGT00530000064112; -.
DR   HOVERGEN; HBG063678; -.
DR   InParanoid; Q96EP0; -.
DR   KO; K11974; -.
DR   OMA; RTNDPEY; -.
DR   OrthoDB; EOG091G01NM; -.
DR   PhylomeDB; Q96EP0; -.
DR   TreeFam; TF350529; -.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   ChiTaRS; RNF31; human.
DR   EvolutionaryTrace; Q96EP0; -.
DR   GeneWiki; RNF31; -.
DR   GenomeRNAi; 55072; -.
DR   PRO; PR:Q96EP0; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000092098; -.
DR   CleanEx; HS_RNF31; -.
DR   ExpressionAtlas; Q96EP0; baseline and differential.
DR   Genevisible; Q96EP0; HS.
DR   GO; GO:0035631; C:CD40 receptor complex; ISS:BHF-UCL.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0071797; C:LUBAC complex; IDA:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0023035; P:CD40 signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; TAS:Reactome.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0097039; P:protein linear polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IDA:UniProtKB.
DR   InterPro; IPR002867; IBR_dom.
DR   InterPro; IPR018997; PUB_domain.
DR   InterPro; IPR026254; RNF31.
DR   InterPro; IPR032065; RNF31-UBA.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR001876; Znf_RanBP2.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR16004; PTHR16004; 1.
DR   Pfam; PF16678; HOIP-UBA; 1.
DR   Pfam; PF01485; IBR; 1.
DR   Pfam; PF09409; PUB; 1.
DR   SMART; SM00647; IBR; 2.
DR   SMART; SM00547; ZnF_RBZ; 3.
DR   SUPFAM; SSF143503; SSF143503; 1.
DR   SUPFAM; SSF90209; SSF90209; 1.
DR   PROSITE; PS50030; UBA; 1.
DR   PROSITE; PS01358; ZF_RANBP2_1; 3.
DR   PROSITE; PS50199; ZF_RANBP2_2; 2.
DR   PROSITE; PS00518; ZF_RING_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Transferase; Ubl conjugation; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN         1   1072       E3 ubiquitin-protein ligase RNF31.
FT                                /FTId=PRO_0000056069.
FT   DOMAIN       71    142       PUB. {ECO:0000255}.
FT   DOMAIN      564    615       UBA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00212}.
FT   ZN_FING     299    329       RanBP2-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00322}.
FT   ZN_FING     350    379       RanBP2-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00322}.
FT   ZN_FING     409    438       RanBP2-type 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00322}.
FT   ZN_FING     699    747       RING-type 1; degenerate.
FT   ZN_FING     779    841       IBR-type.
FT   ZN_FING     860    909       RING-type 2.
FT   REGION        1    485       Polyubiquitin-binding.
FT   REGION      563    616       Interaction with RBCK1.
FT   REGION      910   1072       LDD domain.
FT   MOD_RES     383    383       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     466    466       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1    151       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15093743}.
FT                                /FTId=VSP_014006.
FT   VAR_SEQ      73    630       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_009647.
FT   VAR_SEQ     152    164       EVLLLRTELSLLL -> MDLCTRAGEPSLT (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:15093743}.
FT                                /FTId=VSP_014007.
FT   VAR_SEQ     833    841       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_009648.
FT   VARIANT    1061   1061       V -> I (in dbSNP:rs2277484).
FT                                {ECO:0000269|PubMed:14702039}.
FT                                /FTId=VAR_052102.
FT   MUTAGEN      82     82       Y->A: Abolished interaction with OTULIN.
FT                                {ECO:0000269|PubMed:24726323}.
FT   MUTAGEN      82     82       Y->F: Reduced interaction with OTULIN.
FT                                {ECO:0000269|PubMed:24726323}.
FT   MUTAGEN      85     85       N->A: Reduced interaction with OTULIN.
FT                                {ECO:0000269|PubMed:24726323}.
FT   MUTAGEN      99     99       K->E: Reduced interaction with OTULIN.
FT                                {ECO:0000269|PubMed:24726323}.
FT   MUTAGEN     101    101       N->R: Does not affect interaction with
FT                                OTULIN. {ECO:0000269|PubMed:24726323}.
FT   MUTAGEN     102    102       N->D: Abolished interaction with OTULIN.
FT                                {ECO:0000269|PubMed:24726323}.
FT   MUTAGEN     104    104       V->A: Reduced interaction with OTULIN.
FT                                {ECO:0000269|PubMed:24726323}.
FT   MUTAGEN     699    699       C->S: Abolishes polyubiquitination
FT                                activity of LUBAC; when associated with
FT                                S-702. {ECO:0000269|PubMed:17006537,
FT                                ECO:0000269|PubMed:21455181}.
FT   MUTAGEN     702    702       C->S: Abolishes polyubiquitination
FT                                activity of LUBAC; when associated with
FT                                S-699. {ECO:0000269|PubMed:17006537,
FT                                ECO:0000269|PubMed:21455181}.
FT   MUTAGEN     871    871       C->S: Abolishes polyubiquitination
FT                                activity of LUBAC; when associated with
FT                                S-874. {ECO:0000269|PubMed:17006537,
FT                                ECO:0000269|PubMed:21455181}.
FT   MUTAGEN     874    874       C->S: Abolishes polyubiquitination
FT                                activity of LUBAC; when associated with
FT                                S-871. {ECO:0000269|PubMed:17006537,
FT                                ECO:0000269|PubMed:21455181}.
FT   CONFLICT    529    529       P -> S (in Ref. 1; AAP12522).
FT                                {ECO:0000305}.
FT   CONFLICT    800    800       A -> V (in Ref. 3; BAA91450).
FT                                {ECO:0000305}.
FT   CONFLICT    925    925       H -> R (in Ref. 3; BAB15675).
FT                                {ECO:0000305}.
FT   CONFLICT   1005   1005       Y -> N (in Ref. 3; BAB15675).
FT                                {ECO:0000305}.
FT   CONFLICT   1018   1018       A -> S (in Ref. 3; BAB15675).
FT                                {ECO:0000305}.
FT   CONFLICT   1021   1021       Y -> D (in Ref. 3; BAB15675).
FT                                {ECO:0000305}.
FT   HELIX         4     23       {ECO:0000244|PDB:4P09}.
FT   HELIX        31     38       {ECO:0000244|PDB:4P09}.
FT   HELIX        44     47       {ECO:0000244|PDB:4P09}.
FT   STRAND       49     51       {ECO:0000244|PDB:4P09}.
FT   HELIX        53     58       {ECO:0000244|PDB:4P09}.
FT   HELIX        65     86       {ECO:0000244|PDB:4P09}.
FT   STRAND       88     90       {ECO:0000244|PDB:4P09}.
FT   TURN         93     96       {ECO:0000244|PDB:4P09}.
FT   STRAND       97    102       {ECO:0000244|PDB:4P09}.
FT   HELIX       103    107       {ECO:0000244|PDB:4P09}.
FT   HELIX       109    111       {ECO:0000244|PDB:4P09}.
FT   HELIX       115    122       {ECO:0000244|PDB:4P09}.
FT   STRAND      126    128       {ECO:0000244|PDB:4P09}.
FT   STRAND      131    133       {ECO:0000244|PDB:4P09}.
FT   HELIX       143    164       {ECO:0000244|PDB:4P09}.
FT   HELIX       171    177       {ECO:0000244|PDB:4P09}.
FT   TURN        357    359       {ECO:0000244|PDB:4OWF}.
FT   TURN        371    373       {ECO:0000244|PDB:4OWF}.
FT   HELIX       483    493       {ECO:0000244|PDB:4DBG}.
FT   HELIX       505    515       {ECO:0000244|PDB:4DBG}.
FT   HELIX       521    527       {ECO:0000244|PDB:4DBG}.
FT   HELIX       531    542       {ECO:0000244|PDB:4DBG}.
FT   HELIX       544    546       {ECO:0000244|PDB:4DBG}.
FT   HELIX       551    560       {ECO:0000244|PDB:4DBG}.
FT   TURN        561    563       {ECO:0000244|PDB:4DBG}.
FT   HELIX       565    585       {ECO:0000244|PDB:4DBG}.
FT   HELIX       590    592       {ECO:0000244|PDB:4DBG}.
FT   HELIX       594    600       {ECO:0000244|PDB:4DBG}.
FT   TURN        601    603       {ECO:0000244|PDB:4DBG}.
FT   HELIX       605    616       {ECO:0000244|PDB:4DBG}.
FT   HELIX       618    625       {ECO:0000244|PDB:4DBG}.
FT   TURN        700    702       {ECO:0000244|PDB:5EDV}.
FT   TURN        715    717       {ECO:0000244|PDB:5EDV}.
FT   HELIX       723    735       {ECO:0000244|PDB:5EDV}.
FT   HELIX       739    741       {ECO:0000244|PDB:5EDV}.
FT   TURN        745    747       {ECO:0000244|PDB:5EDV}.
FT   TURN        756    759       {ECO:0000244|PDB:5EDV}.
FT   HELIX       760    772       {ECO:0000244|PDB:5EDV}.
FT   HELIX       775    790       {ECO:0000244|PDB:5EDV}.
FT   STRAND      792    798       {ECO:0000244|PDB:5EDV}.
FT   STRAND      800    803       {ECO:0000244|PDB:5EDV}.
FT   STRAND      805    811       {ECO:0000244|PDB:5EDV}.
FT   STRAND      813    816       {ECO:0000244|PDB:5EDV}.
FT   TURN        818    820       {ECO:0000244|PDB:5EDV}.
FT   STRAND      823    825       {ECO:0000244|PDB:5EDV}.
FT   TURN        826    828       {ECO:0000244|PDB:5EDV}.
FT   HELIX       834    836       {ECO:0000244|PDB:5EDV}.
FT   HELIX       841    851       {ECO:0000244|PDB:5EDV}.
FT   HELIX       859    864       {ECO:0000244|PDB:4LJO}.
FT   STRAND      868    870       {ECO:0000244|PDB:4LJO}.
FT   TURN        872    874       {ECO:0000244|PDB:4LJO}.
FT   STRAND      877    879       {ECO:0000244|PDB:4LJO}.
FT   STRAND      886    889       {ECO:0000244|PDB:4LJO}.
FT   TURN        891    893       {ECO:0000244|PDB:4LJO}.
FT   STRAND      896    898       {ECO:0000244|PDB:4LJO}.
FT   TURN        899    901       {ECO:0000244|PDB:4LJO}.
FT   STRAND      904    906       {ECO:0000244|PDB:4LJO}.
FT   TURN        917    920       {ECO:0000244|PDB:4LJO}.
FT   STRAND      921    924       {ECO:0000244|PDB:4LJO}.
FT   STRAND      928    930       {ECO:0000244|PDB:5EDV}.
FT   HELIX       931    934       {ECO:0000244|PDB:4LJO}.
FT   HELIX       939    948       {ECO:0000244|PDB:4LJO}.
FT   STRAND      965    968       {ECO:0000244|PDB:4LJP}.
FT   STRAND      972    977       {ECO:0000244|PDB:4LJO}.
FT   STRAND      980    985       {ECO:0000244|PDB:4LJO}.
FT   HELIX       999   1012       {ECO:0000244|PDB:4LJO}.
FT   HELIX      1017   1020       {ECO:0000244|PDB:4LJO}.
FT   HELIX      1023   1034       {ECO:0000244|PDB:4LJO}.
FT   HELIX      1046   1060       {ECO:0000244|PDB:4LJO}.
FT   STRAND     1065   1067       {ECO:0000244|PDB:4LJO}.
SQ   SEQUENCE   1072 AA;  119652 MW;  CFAD183A14F764BA CRC64;
     MPGEEEERAF LVAREELASA LRRDSGQAFS LEQLRPLLAS SLPLAARYLQ LDAARLVRCN
     AHGEPRNYLN TLSTALNILE KYGRNLLSPQ RPRYWRGVKF NNPVFRSTVD AVQGGRDVLR
     LYGYTEEQPD GLSFPEGQEE PDEHQVATVT LEVLLLRTEL SLLLQNTHPR QQALEQLLED
     KVEDDMLQLS EFDPLLREIA PGPLTTPSVP GSTPGPCFLC GSAPGTLHCP SCKQALCPAC
     DHLFHGHPSR AHHLRQTLPG VLQGTHLSPS LPASAQPRPQ STSLLALGDS SLSSPNPASA
     HLPWHCAACA MLNEPWAVLC VACDRPRGCK GLGLGTEGPQ GTGGLEPDLA RGRWACQSCT
     FENEAAAVLC SICERPRLAQ PPSLVVDSRD AGICLQPLQQ GDALLASAQS QVWYCIHCTF
     CNSSPGWVCV MCNRTSSPIP AQHAPRPYAS SLEKGPPKPG PPRRLSAPLP SSCGDPEKQR
     QDKMREEGLQ LVSMIREGEA AGACPEEIFS ALQYSGTEVP LQWLRSELPY VLEMVAELAG
     QQDPGLGAFS CQEARRAWLD RHGNLDEAVE ECVRTRRRKV QELQSLGFGP EEGSLQALFQ
     HGGDVSRALT ELQRQRLEPF RQRLWDSGPE PTPSWDGPDK QSLVRRLLAV YALPSWGRAE
     LALSLLQETP RNYELGDVVE AVRHSQDRAF LRRLLAQECA VCGWALPHNR MQALTSCECT
     ICPDCFRQHF TIALKEKHIT DMVCPACGRP DLTDDTQLLS YFSTLDIQLR ESLEPDAYAL
     FHKKLTEGVL MRDPKFLWCA QCSFGFIYER EQLEATCPQC HQTFCVRCKR QWEEQHRGRS
     CEDFQNWKRM NDPEYQAQGL AMYLQENGID CPKCKFSYAL ARGGCMHFHC TQCRHQFCSG
     CYNAFYAKNK CPEPNCRVKK SLHGHHPRDC LFYLRDWTAL RLQKLLQDNN VMFNTEPPAG
     ARAVPGGGCR VIEQKEVPNG LRDEACGKET PAGYAGLCQA HYKEYLVSLI NAHSLDPATL
     YEVEELETAT ERYLHVRPQP LAGEDPPAYQ ARLLQKLTEE VPLGQSIPRR RK
//
